Neurocrine Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences has finalized its strategic acquisition of Soleno Therapeutics, a move that significantly expands its footprint in the rare disease arena. The $2.9 billion transaction injects Soleno's flagship product, VYKAT XR, into Neurocrine's commercial arsenal, marking a pivotal moment for both companies and the Prader-Willi syndrome (PWS) community.

VYKAT XR, recently granted U.S. Food and Drug Administration approval, stands as the sole therapeutic option addressing hyperphagia, a hallmark symptom of PWS. This condition, affecting an estimated 10,000 individuals in the United States, is a complex genetic disorder characterized by relentless hunger and compulsive food-seeking behaviors, posing severe health challenges. The drug's availability for both adult and pediatric patients aged four and older with PWS-related hyperphagia underscores its critical role in managing this life-threatening condition.

The integration of VYKAT XR complements Neurocrine's existing portfolio, which includes established treatments like INGREZZA and CRENESSITY. This expansion aligns with Neurocrine's stated mission to address significant unmet medical needs, particularly within endocrinology and rare genetic disorders. The acquisition, initially announced in early April, saw Neurocrine successfully complete a cash tender offer for Soleno shares at $53.00 per share. This offer garnered substantial support, with approximately 88.9% of Soleno's outstanding common stock tendered by mid-May.

Following the tender offer, Neurocrine executed a merger, making Soleno Therapeutics a wholly owned subsidiary. This structure ensures that all remaining shareholders will receive the same $53 per share cash consideration, facilitating a clean transition. Consequently, Soleno's common stock has concluded its trading on the Nasdaq Capital Market. The successful closure of this deal highlights the increasing strategic importance of targeted therapies for rare conditions within the biotechnology sector, a trend supported by robust investor interest in companies with differentiated pipelines.

The market for rare disease treatments continues to demonstrate strong growth potential, driven by advancements in genetic understanding and a growing demand for specialized therapeutic solutions. Companies like Neurocrine are strategically positioning themselves to capitalize on this trend by acquiring innovative assets that address significant patient populations with limited or no existing treatment options. The $2.9 billion valuation reflects the perceived value and future revenue potential of VYKAT XR within the PWS market.

Financial advisory for this significant transaction was provided by industry leaders. Goldman Sachs served as the exclusive financial advisor to Neurocrine Biosciences, with Cooley LLP providing legal counsel. Soleno Therapeutics received financial guidance from Centerview Partners LLC and Guggenheim Securities, LLC, while Wilson Sonsini Goodrich & Rosati acted as its legal advisor. This robust financial and legal support underscores the complexity and importance of the deal.

Dr. Kyle W. Gano, CEO of Neurocrine Biosciences, expressed enthusiasm for the integration, stating, “Today marks an important advancement in Neurocrine’s mission to deliver life-changing treatments for patients with significant unmet needs. We welcome our Soleno colleagues to Neurocrine and share their deep commitment to the Prader-Willi syndrome community, and we look forward to working together to make VYKAT XR available to more patients and their families.” This sentiment signals a unified approach to patient care and market penetration.